Form 4: Mirum CEO Exercises Stock Options, Boosts Direct Stake

Mirum Pharmaceuticals CEO Christopher Peetz exercised 19,133 stock options, acquiring common stock at $19.24 per share, increasing his direct beneficial ownership.

Summary

• Christopher Peetz, Chief Executive Officer and Director of Mirum Pharmaceuticals, Inc. (MIRM), reported an insider transaction.
• On November 18, 2025, Mr. Peetz exercised employee stock options to acquire 19,133 shares of Mirum Pharmaceuticals common stock.
• The acquisition price for these shares was $19.24 per share.
• Following this transaction, Mr. Peetz directly beneficially owns 158,034 shares of common stock.
• This direct ownership includes 260 shares acquired on November 10, 2025, through the Issuer's Employee Stock Purchase Plan.
• Mr. Peetz also indirectly beneficially owns 208,570 shares of common stock through The Peetz Family Trust.
• After the option exercise, 150,867 employee stock options remain directly beneficially owned by Mr. Peetz.
• The exercised stock options were fully vested and had an expiration date of January 9, 2030.

Sentiment

Score: 6

Explanation: The exercise of stock options by the CEO to acquire common stock is generally viewed as a positive signal, indicating management's confidence in the company's future prospects. However, it is also a routine part of executive compensation and does not necessarily imply a strong bullish stance beyond the existing compensation structure.

Positives

• CEO Christopher Peetz increased his direct beneficial ownership of Mirum Pharmaceuticals common stock by 19,133 shares through option exercise, demonstrating continued confidence in the company's future.
• The exercise price of $19.24 indicates the options were in-the-money, suggesting the stock price was above this level at the time of exercise.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitors.

Related Party Transactions

• Indirect beneficial ownership of 208,570 shares of common stock is held by The Peetz Family Trust, which is a related party.

Stakeholder Impact

• Shareholders: Increased direct ownership by the CEO may be perceived as a positive signal of management's alignment with shareholder interests.
• Employees: The filing mentions the Employee Stock Purchase Plan (ESPP), indicating a broader equity compensation program for employees.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Christopher Peetz, CEO, Director, Form 4, insider transaction, stock options, equity compensation, beneficial ownership, common stock